跳至主要内容
临床试验/NL-OMON54813
NL-OMON54813招募中不适用

The effect of galacto-oligosaccharides (GOS) or chicory fructo-oligosaccharides (FOS) versus a placebo on bowel habits in children with functional constipation. - The Inside Study

Wageningen Universiteit0 个研究点目标入组 198 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
198

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 11(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria, as considered by a medical doctor:
  • - Written informed consent obtained from parents or guardians of toddlers
  • meeting the eligibility criteria and those willing to comply with the
  • requirements of the study
  • - Aged 1-6 years (12 to 72 months at the day of inclusion) (at least 25% 1-2
  • years of age and at least 25% 2-3 years of age)
  • - Children that meet the following (Rome IV criteria): must include 1 month of
  • at least 2 of the following in infants up to 4 years of age:
  • 1. 2 or fewer defecations per week
  • 2. History of excessive stool retention
  • 3. History of painful or hard bowel movements
  • 4. History of large-diameter stools
  • 5. Presence of a large fecal mass in the rectum
  • In toilet-trained children, the following additional criteria may be used:
  • 6. At least 1 episode/week of incontinence after the acquisition of toileting
  • 7. History of large-diameter stools that may obstruct the toilet

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • - Children who suffer from any other GI complaints than FC, known structural GI
  • abnormalities, or previous GI surgery
  • - Any condition that would make it unsafe for the child to participate. This
  • can include developmental delays associated with musculoskeletal or neurologic
  • conditions affecting the gastrointestinal tract. Children with underlying cause
  • of defecation disorder (for example: Hirschsprung*s disease, spina bifida
  • occulta, cystic fibrosis, or gastrointestinal malformations).
  • - Children with clinically significant cardiac, vascular, liver, pulmonary,
  • psychiatric disorders, severe renal insufficiency, human immunodeficiency
  • virus, acquired immunodeficiency syndrome, hepatitis B or C or known
  • abnormalities of haematology, urinalysis, or blood biochemistry, as checked by
  • the inclusion questionnaire.
  • - Children who are lactose intolerant for whom it is expected that low doses of
  • lactose could lead to diarrhoea or children that are allergic to cow*s milk
  • (GOS is derived from cow*s milk)
  • - Children who are allergic to fish
  • - Use of antibiotics or breast-feeding 4 weeks prior to the study
  • - Other medicines or food supplements, which can influence defecation and gut
  • microbiota 1 week prior to the study run-in period. This includes e.g. infant
  • formula(IF), follow-on formula (FOF) and young child formula (YCF), or products
  • with labelled pre-and probiotics in the previous week prior to the study run-in
  • - Children on other supplements/ medication that would affect bowel function
  • e.g. fibre supplements, and pre-, pro- and synbiotics (excluding escape
  • medication during the trial as mentioned in chapter 3 and 5.3) for the past
  • - Children that participate in another clinical trial.

研究者

相似试验